Angiotech partner to release broad range of clinical study results on market-leading TAXUS(R) Coronary Stent System at ACC 2006
07 März 2006 - 7:32PM
PR Newswire (US)
Results highlight efficacy of TAXUS in most complex lesions and
highest risk patients VANCOUVER, March 7 /PRNewswire-FirstCall/ --
Angiotech Pharmaceuticals, Inc.(NASDAQ: ANPI; TSX: ANP) corporate
partner Boston Scientific Corporation ("BSC") today announced the
schedule of BSC's major events at the annual American College of
Cardiology Scientific Session, which runs from March 11 to 14 in
Atlanta, Georgia. Sunday, March 12 ---------------- - TAXUS V ISR
Results. At 10:00 a.m., BSC will release nine-month results from
the TAXUS V In-Stent Restenosis (ISR) clinical trial, which
evaluates the TAXUS Express2 paclitaxel-eluting coronary stent
system versus vascular brachytherapy for the treatment of bare
metal stent in-stent restenosis. The TAXUS V ISR trial is a
prospective, randomized, open-label trial with a primary endpoint
of target vessel revascularization (TVR) at nine months. The trial
has enrolled 396 patients at 37 sites in the U.S. The results will
be presented by Gregg W. Stone, M.D., the study's Principal
Investigator, at a podium session in Hall C3 of the Georgia World
Congress Center. BSC will also issue a press release at this time.
The TAXUS V ISR results are scheduled to be published in the March
15 issue of The Journal of the American Medical Association (JAMA)
with an advanced posting to its website on March 12 at
http://jama.ama-assn.org/. - STENT Registry. At 9:40 a.m.,
nine-month results from the Strategic Transcatheter Evaluation of
New Therapies (STENT) registry will be presented by Charles A.
Simonton III, M.D., chairman of the executive steering committee
for the STENT registry, at a podium session in Hall C3 of the
Georgia World Congress Center. This large, independent,
prospective, multicenter registry evaluates the comparative late
clinical outcomes of paclitaxel- and sirolimus- eluting coronary
stents among "real-world" cases and clinical situations, including
diabetics and other high-risk patients. With a planned enrollment
of more than 8,000 patients, the STENT registry is the largest
study of its kind in the United States. - DES Educational
Symposium. From 8:00-10:00 p.m., BSC will host a symposium
entitled, "Contemporary DES Data: A Clear Way to Put It All into
Perspective" in the Grand Ballroom, North Tower of the Omni Hotel
at the CNN Center. The symposium will be chaired by Stephen G.
Ellis, M.D. and Patrick W. Serruys, M.D., Ph.D. The event will
include case-based presentations and interactive sessions on the
latest clinical evidence and "real-world" registry data for drug-
eluting stents in complex patients. BSC will also host a reception
prior to the symposium from 7:00 to 8:00 p.m. adjacent to the Grand
Ballroom. Tuesday, March 14 ----------------- - ARRIVE II Registry
data. BSC will release six-month results from its ARRIVE II
registry, which has enrolled 5,007 consecutive patients at
approximately 53 centers in the United States. The program is
designed to collect and analyze "real-world" safety and clinical
outcomes data from the TAXUS Express2 paclitaxel-eluting stent
system in the treatment of patients with coronary artery disease.
The results will be presented by Malcolm Foster, M.D., an
investigator for the study, from 10:00-11:00 a.m. at a poster
session in Hall B1 of the Georgia World Congress Center. BSC will
also issue a press release at this time. BSC acquired worldwide
exclusive rights from Angiotech to use paclitaxel to coat its
coronary stent products and has co-exclusive rights to other
vascular and non-vascular products. About Angiotech Pharmaceuticals
Vancouver-based Angiotech Pharmaceuticals, Inc. is a specialty
pharmaceutical company pioneering the combination of pharmaceutical
compounds with medical devices and biomaterials to both create
novel solutions for poorly addressed disease states and improve
surgical outcomes. To find out more about Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please
visit our website at http://www.angiotech.com/. Statements
contained herein that are not based on historical or current fact,
including without limitation statements containing the words
"anticipates," "believes," "may," "continue," "estimate,"
"expects," and "will" and words of similar import, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Such factors include, among others, the following:
general economic and business conditions, both nationally and in
the regions in which the Company operates; technology changes;
competition; changes in business strategy or development plans; the
ability to attract and retain qualified personnel; existing
governmental regulations and changes in, or the failure to comply
with, governmental regulations; liability and other claims asserted
against the Company; and other factors referenced in the Company's
filings with the United States Securities and Exchange Commission
or the Canadian securities regulators. Given these uncertainties,
readers are cautioned not to place undue reliance on such
forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements. FOR ADDITIONAL
INFORMATION: --------------------------- Analysts and Investors:
Rui Avelar, Chief Medical Officer Angiotech Pharmaceuticals, Inc.
(604) 221-7676 ext 6933 Media: Colleen Beauregard Waggener Edstrom
Bioscience (503) 443-7863, Email: DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Analysts and Investors: Rui Avelar,
Chief Medical Officer, Angiotech Pharmaceuticals, Inc., (604)
221-7676 ext 6933; Media: Colleen Beauregard, Waggener Edstrom
Bioscience, (503) 443-7863, Email:
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024